The BODY text on this A/W is at:

Dimensions


DESCRIPTION:

CAUTION:

For use in dogs and cats

For veterinary oral suspension

β resist destruction by β-lactamase-producing strains of both gram-positive and gram-negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, both lactamase-producing strains of both gram-positive and gram-negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including Staphylococcus aureus*, Staphylococcus epidermidis, Staphylococcus intermedius, Staphylococcus haemolyticus, Staphylococcus species*. Clavulanic acid by itself has only weak antibacterial activity. Chemically, it is D(-)-3-oxo-y-hydroxybenzyl penicillin c-lactamase-producing strains of both gram-positive and gram-negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including Staphylococcus aureus*, Staphylococcus epidermidis, Staphylococcus intermedius, Staphylococcus haemolyticus, Staphylococcus species*. Clavulanic acid by itself has only weak antibacterial activity. Chemically, it is D(-)-3-oxo-y-hydroxybenzyl penicillin c-clavulanate potassium) is an orally administered antibiotic. It is the active ingredient of Augmentin® (amoxicillin trihydrate/clavulanate potassium). For use in dogs and cats. Cats: Skin and soft tissues infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus haemolyticus, Staphylococcus species*, Enterococcus species, Klebsiella species, Citrobacter species, Proteus species, and Providencia species. Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and therapeutic indices. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease. The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Clavamox combines the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxicillin to include β-lactamase-producing as well as non-β-lactamase-producing aerobic and anaerobic organisms.

Microbiology: Amoxicillin is bactericidal in action and acts through the inhibition of biosynthesis of peptidoglycan at the bacterial cell wall.

The susceptibility of these organisms has also been demonstrated in in vivo studies. Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus haemolyticus, Staphylococcus species*, Enterococcus species, Klebsiella species, Citrobacter species, Proteus species, and Providencia species. Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and therapeutic indices. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease. The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

The use of this drug is contraindicated in animals with a history of an allergic reaction to β-lactam antibiotics or cephalosporins. Warnings: Safety of use in pregnant or breeding animals has not been determined. For use in dogs and cats only. Adverse reactions: Clavamox contains a semisynthetic penicillin (amoxicillin) and has the potential to cause allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids. Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and therapeutic indices. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease. The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.

Dogs: The recommended dosage is 6.25 mg/lb (1.4 mg/kg) q24h for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. In pregnant patients, therapy may require treatment for 31 days; the maximum duration of treatment should not exceed 30 days.
Cats: The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.

Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.

Reconstitution instructions – Oral Suspension: Add 14 mL of water to the 15-mL bottle and shake vigorously. Each mL of suspension will contain 50 mg of amoxicillin activity as the trihydrate and 12.5 mg of clavulanic acid activity as the potassium salt.

Note: Any unused portion of the reconstituted suspension must be discarded after 10 days. Refrigeration of the reconstituted suspension is required.

HOW SUPPLIED: Clavamox Drops are supplied in 15-mL bottles containing 50 mg of amoxicillin/12.5 mg of clavulanic acid per mL.

NADA #55-101, Approved by FDA

Clavamox is a trademark owned by and used under license from GlaxoSmithKline.

Augmentin is a trademark owned by GlaxoSmithKline.

Manufactured by: Hembrow Laboratories Ltd.
Newry, N. Ireland, UK

Distributed by: Zoetis Inc.
Kalamazoo, MI 49007

Revised: July 2014

Date: 11 Sep 2014

Time: 10:26

Description: CLAVAMOX

Market: US

Supplier: Norbrook

Component: Insert

Supplier #: 23854401

Pharma Code: N/A

Perigord #: 390002

Colours: Black

Perigord house
Darnestown Industrial Park
Guide: 15

Dimensions: 146 x 294 mm

Drawing Number: N/A

TEXT SIZE

The BODY text on this A/W is at:

9 pt